Result of AGM

RNS Number : 3098Q

Cizzle Biotechnology Holdings PLC

27 June 2022

 

27 June 2022

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

Result of AGM

Cizzle Biotechnology, the UK based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a poll and were passed.

The votes cast in respect of the resolutions were as follows:

Resolution	For		Against		Votes withheld
	Total votes	%	Total votes	%
1.  That the Annual Report and Accounts for the year ended 31 December 2021 be received	55,444,064	100.00%	0	0.00%	30,000
2.  For the approval of the Directors' Remuneration Policy which takes effect immediately after the end of the AGM	55,297,384	94.84%	90,139	0.16%	86,541
3.  For the approval of the Remuneration Report set out on pages 21 to 26 of the annual report	55,297,584	99.84%	90,139	0.16%	86,341
4.  For the re-election of John Treacy as a director of the Company	55,444,064	100.00%	0	0.00%	30,000
5.  For the re-election of Nigel Lee as a director of the Company	55,444,064	100.00%	0	0.00%	30,000
6.  For the re-election of Dawn Coverley as a director of the Company	55,409,864	99.94%	34,200	0.06%	30,000
7.  For the re-appointment of PKF Littlejohn LLP as auditors to the Company.	55,444,064	100.00%	0	0.00%	30,000
8.  Authorises the Directors to determine the remuneration of the auditors	55,388,125	99.90%	55,939	0.10%	30,000
9.  Authorises the directors to allot shares pursuant to Section 551 of the Companies Act 2006	54,796,868	99.89%	58,814	0.11%	618,382
10.  Authorises the directors to allot equity securities pursuant to Section 570 of the Companies Act 2006	52,358,832	94.62%	2,979,293	5.38%	135,939
11.  For the approval of the adoption of the new Articles of Association	55,444,064	100.00%	0	0.00%	30,000
12.  For the calling of general meetings on not less than 14 clear days' notice	55,444,064	100.00%	0	0.00%	30,000

Enquiries:

Cizzle Biotechnology Holdings plc	Via IFC Advisory
Allan Syms (Executive Chairman)

Allenby Capital Limited	[phone]
John Depasquale
Alex Brearley

Novum Securities Limited	[phone]
Colin Rowbury Jon Bellis

IFC Advisory Limited	[phone]
Tim Metcalfe	[e-mail]
Florence Chandler

Notes to Editors:

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test for the early detection of lung cancer.  Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues .  Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

 

END

 

 

RAGSEUFSWEESELM